drugset / Trial / NCT05229042

A Study to Investigate the Safety and Efficacy of Ricolinostat

NCT05229042

Phase 1 Completed 10 enrolled Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a double-blind, placebo-controlled study during which patients will receive ricolinostat or placebo.

Timeline

Start
2022-01-01
Primary completion
2023-11-10
Completion
2023-11-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ricolinostat Small molecule Oral